Medicaid Provider Spending

$1.09 trillion in Medicaid claims data, 2018–2024 · 617K+ providers

SMITH, MARTHA

NPI: 1922035492 · KNOXVILLE, TN 37909 · Anesthesiology Physician · NPI assigned 06/28/2006

$89K
Total Medicaid Paid
8,630
Total Claims
7,618
Beneficiaries
10
Codes Billed
2018-01
First Month
2022-02
Last Month

Monthly Spending Trend

Yearly Breakdown

YearClaimsTotal Paid
2018 1,851 $22K
2019 3,182 $38K
2020 2,539 $28K
2021 969 $0.00
2022 89 $0.00

Billing Codes

CodeDescriptionClaimsBeneficiariesTotal Paid
99214 Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity 4,315 3,723 $58K
99204 Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity 240 221 $12K
G0483 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed 242 223 $8K
99213 Office or other outpatient visit for the evaluation and management of an established patient, low complexity 327 298 $5K
99211 Office or other outpatient visit for the evaluation and management of an established patient, minimal severity 639 609 $2K
80307 Drug test(s), presumptive, any number of drug classes; immunoassay 181 175 $2K
G0482 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed 44 38 $911.41
64493 20 13 $534.06
99072 123 102 $0.00
99000 2,499 2,216 $0.00